Skip to main content
. 2021 Dec 10;106(1):25–56. doi: 10.1007/s00253-021-11713-0

Fig. 2.

Fig. 2

Distribution of the clinical trial phases for new vaccines against infection diseases in humans based on novel technologies applied to the European Medicines Agency (EMA, a) or the Food and Drug Administration (FDA, b)